Thyrocare Margin Hits 32% Amid Imaging Unit Drag

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Thyrocare Margin Hits 32% Amid Imaging Unit Drag
Overview

Thyrocare Technologies announced a robust 36.7% year-on-year increase in net profit to ₹26.1 crore for its December quarter, propelled by strong volume growth in its core business. Revenue climbed 19.3% to ₹182 crore, while a surge in operating leverage expanded EBITDA margins significantly to 32% from 26% a year ago. However, this impressive performance from the diagnostics division masks ongoing weakness in its imaging services segment, which continued to post losses.

The strong quarterly results were primarily driven by substantial gains in operating efficiency and scale. This performance contrasts sharply with the pre-announcement analyst consensus, which had anticipated a potential decline in profitability. The company's standalone profit before tax reached ₹36.6 crore, a figure that includes a ₹6 crore charge for exceptional items related to new labour codes and one-time restructuring costs, according to its exchange filing. Shares finished the session 1.01% higher at ₹458.10 just before the results were made public.

A Tale of Two Segments

Thyrocare's financial results reveal a clear divergence in performance between its two main business units. The Diagnostic Testing Services segment was the undisputed engine of growth, with revenue climbing to ₹182.4 crore from ₹151.9 crore in the same quarter last year. This division delivered a segment profit before tax of ₹36.8 crore, underscoring its powerful operating leverage and contribution to the overall margin expansion. In stark contrast, the Imaging Services segment reported nearly flat revenue of ₹12.4 crore and continued to be a drag on profitability, posting a segment loss of ₹1.1 crore. This ongoing struggle in the radiology vertical highlights a critical challenge for the company, even as its core pathology business thrives.

The Competitive & Valuation Checkup

Thyrocare's 32% EBITDA margin represents a strong performance within the Indian diagnostics sector. For comparison, key competitors like Dr. Lal PathLabs have recently operated with EBITDA margins in the 26-31% range. Metropolis Healthcare, another major peer, recently announced a 26% year-on-year revenue surge for the same quarter, indicating intense competition and a robust market environment. Following the results, Thyrocare's TTM P/E ratio stands at approximately 55-57, which is notably higher than Dr. Lal PathLabs' P/E of around 44 but comparable to Metropolis Healthcare's P/E of about 59. This premium valuation suggests the market has largely priced in the strong growth from the diagnostics arm but may be overlooking the persistent lag from the imaging business.

Future Outlook & Sector Trends

Looking forward, the company's ability to either turn around or restructure its loss-making imaging segment will be a key focus for investors. The broader Indian diagnostics industry is undergoing a consolidation phase, with organized players gaining market share from the unorganized sector. Trends for 2026 point towards greater integration of technology, AI-driven diagnostics, and a focus on standardized quality across Tier-2 and Tier-3 cities. While analyst ratings have been largely positive, citing strong management and a debt-free balance sheet, the stock's 'very expensive' valuation remains a point of caution. The company's performance in the upcoming quarters will be crucial in justifying its current market premium.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.